TLR7-Selective Agonist Compounds for Lower-Toxicity Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing TLR7 agonists face challenges in systemic administration due to a narrow therapeutic window and dose-limiting toxicity, limiting their effectiveness in treating cancer and infections.
Innovation Solution
Development of TLR7 agonist compounds that selectively activate TLR7 with minimal activation of TLR8, formulated into pharmaceutical compositions for therapeutic and prophylactic applications, including combinations with other therapeutic agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TLR7 agonists are administered systemically to treat cancer and infections, then immune response stimulation is improved, but toxicity increases and therapeutic window narrows
Solution Approach 1:
The patent uses TLR7-selective agonists as intermediaries that specifically target TLR7 receptors on plasmacytoid dendritic cells without substantially activating TLR8 receptors. This selective mediation allows immune response stimulation while avoiding the dose-limiting toxicity associated with non-selective TLR7/8 agonists, thereby resolving the contradiction between effectiveness and toxicity
Solution Approach 2:
The invention applies local quality by designing compounds with specific molecular structures (such as modified imidazoquinoline cores with particular substituent patterns) that confer TLR7 selectivity. This structural differentiation ensures the agonist interacts preferentially with TLR7, enabling effective immune activation at lower doses without the harmful effects of TLR8 activation
2Reliability
If TLR7 agonists are used to stimulate immune response, then cytokine production and interferon induction are improved, but TLR8 activation causes reduced selectivity
Solution Approach 1:
The patent employs asymmetry in molecular design by creating TLR7-selective agonists with asymmetric substituent patterns on the imidazoquinoline core. This asymmetric structure creates steric and electronic properties that favor binding to TLR7 over TLR8, achieving both effective immune activation and high receptor selectivity simultaneously
Solution Approach 2:
The invention utilizes parameter changes by systematically modifying molecular properties such as substituent types, positions, and configurations on the TLR7 agonist scaffold. These parameter adjustments fine-tune the compound's selectivity profile, ensuring preferential TLR7 activation while minimizing TLR8 engagement, thus resolving the selectivity contradiction
3Productivity
If narrow therapeutic window of TLR7 agonists is overcome by dose optimization, then treatment effectiveness is improved, but dose-limiting toxicity remains
Solution Approach 1:
The patent converts the potential harm of TLR8 activation into a benefit by designing TLR7-selective agonists that deliberately avoid TLR8 engagement. This selective approach transforms the original problem of off-target activation into an advantage, allowing effective dosing without the dose-limiting toxicity that plagues non-selective agonists, thereby simultaneously improving productivity and reducing harmful factors
Data Source
AI summary
The present invention relates to TLR7 agonists according to Formula I and their use in the treatment of diseases such as cancer and infectious disease.